Prevention of Hepatitis C Virus (HCV) and HIV-1 Co-Infections
A collaborative project financed by the EC Framework Programme 7
PEACHI-03 Clinical Trial Update
Following the completion of Work Package 1 (Production of clinical lots and approval for use in clinical trials), work has begun on PEACHI-03 (safety and immunogenicity of second generation viral vectored technology using ChAd3 and MVA, employing NSmut linked to the human MHC class II invariant chain, in both healthy subjects and HIV-positive patients).
The protocol for the healthy volunteer and DAA-treated patient arms has been completed and currently is under review by the relevant UK regulatory bodies. Recruitment is scheduled to begin in September 2017.
PEACHI-04 Clinical Trial Update
The final volunteer visit has now taken place for clinical trial PEACHI-04 (evaluation of the safety and immunogenicity of simultaneous prime-boost immunisations with candidate HCV and HIV-1 vaccines).
PEACHI-02 Clinical Trial Update
The last participant last visit has now taken place for PEACHI-02 (evaluation of the safety and immunogenicity of prime-boost immunisations with candidate HCV vaccines in HIV seropositive individuals).
The final annual meeting of the PEACHI consortium was held on 12th-13th July 2017 in St Gallen, Switzerland. The meeting gave researchers an excellent opportunity to discuss the findings of the clinical trials and summarise project achievements.